Ikena Oncology, Inc. (IKNA)
$4.29
-0.19 (-4.24%)
Rating:
Recommendation:
-
Symbol | IKNA |
---|---|
Price | $4.29 |
Beta | 0.000 |
Volume Avg. | 0.09M |
Market Cap | 155.545M |
Shares () | - |
52 Week Range | 1.94-11.79 |
1y Target Est | - |
DCF Unlevered | IKNA DCF -> | |
---|---|---|
DCF Levered | IKNA LDCF -> | |
ROE | -28.27% | Sell |
ROA | -27.23% | Sell |
Operating Margin | - | |
Debt / Equity | 19.95% | Neutral |
P/E | 5.36 | Buy |
P/B | 0.98 | Buy |
Latest IKNA news
About
Download (Excel)Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.